Frontotemporal dementia
- PMID: 38081627
- PMCID: PMC10718268
- DOI: 10.1503/cmaj.230407
Frontotemporal dementia
Conflict of interest statement
Competing interests: Mario Masellis reports grant funding from the Ontario Brain Institute, the Canadian Institutes of Health Research, Woman’s Brain Health Initiative, Brain Canada, Weston Brain Institute, Washington University, Roche and Alector Pharmaceuticals. He has received royalties from Henry Stewart Talks and consulting fees from Ionis Pharmaceuticals, Alector Pharmaceuticals, Wave Life Sciences, Biogen Canada and Eisai. He is a board member with the Alzheimer’s Society Canada and Parkinson Canada. No other competing interests are declared.
References
-
- Sivasathiaseelan H, Marshall CR, Agustus JL, et al. . Frontotemporal dementia: a clinical review. Semin Neurol 2019;39:251–63. - PubMed
-
- Karageorgiou E, Miller BL. Frontotemporal lobar degeneration: a clinical approach. Semin Neurol 2014;34:189–201. - PubMed
-
- Magrath Guimet N, Zapata-Restrepo LM, Miller BL. Advances in treatment of frontotemporal dementia. J Neuropsychiatry Clin Neurosci 2022;34:316–27. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources